Exhibit 99.1
Alnylam Pharmaceuticals Reports First
Quarter 2006 Financial Results; Company Achieves Multiple Milestones
and Recognizes Increased Revenue from Pharmaceutical Partners
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2006--Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today reported its consolidated financial results for the
quarter ended March 31, 2006 and company highlights.
"We have made considerable progress on multiple fronts since the
beginning of the year, including a significant increase in revenue due
to R&D funding from our pharmaceutical alliances, funding which we
expect to form the basis for continued and sustainable revenues over
the next several years," said John Maraganore, Ph.D., President and
Chief Executive Officer of Alnylam. "Our lead program, ALN-RSV01, an
RNAi therapeutic for the treatment of RSV infection, was found to be
safe and well tolerated in Phase I trials, setting the stage for
further development of this program. We signed yet another alliance
this quarter, with Novartis for pandemic flu. This is our fifth major
alliance to date, and we expect more in the future. Our scientific
leadership was highlighted with the publication in the journal Nature
of our non-human primate pre-clinical efficacy data, an event we
believe represents significant 'de-risking' for systemic delivery of
RNAi therapeutics. Finally, we made major progress in what we believe
is the industry's leading RNAi intellectual property estate with the
allowance in the U.S. of claims in the 'Tuschl II' patent series, held
exclusively for therapeutics by Alnylam, which broadly cover methods
for making small interfering RNAs, or siRNAs."
Cash, Cash Equivalents and Marketable Securities
At March 31, 2006, Alnylam had cash, cash equivalents and
marketable securities of $132.3 million, compared to $80.0 million at
December 31, 2005. The increase was primarily due to $62.2 million of
net proceeds from the company's public offering of approximately 5.1
million shares of common stock in January 2006.
Net Loss
The net loss according to accounting principles generally accepted
in the U.S. (GAAP) for the quarter ended March 31, 2006 was $8.9
million, or $0.30 per share, as compared to $6.6 million, or $0.32 per
share, in the first quarter of 2005.
Revenues
Revenues in the first quarter of 2006 were $5.7 million, a
significant increase from $1.6 million during the first quarter of
2005. Included in revenues in the first quarter of 2006 was $4.4
million of cost reimbursement and amortization revenues related to the
company's main collaboration with Novartis, $0.8 million of cost
reimbursement revenues related to its Novartis flu collaboration as
well as $0.3 million of cost reimbursement and amortization revenues
related to its Merck collaborations.
Research and Development Expenses
Research and development (R&D) expenses were $11.9 million in the
first quarter of 2006, including $1.5 million of non-cash stock-based
compensation, as compared to $5.4 million in the first quarter of
2005, which included $0.2 million of non-cash stock-based
compensation. The increase in R&D expenses was primarily due to
clinical trial and manufacturing-related expenses in support of our
clinical program for respiratory syncytial virus (RSV) infection which
began in December 2005. Also contributing to the increase were higher
external service costs associated with the company's RNAi therapeutic
programs and costs related to an increase in R&D headcount over the
past year to support the company's expanding pipeline and alliances.
These increases were partially offset by lower expenses related to our
age-related macular degeneration program, for which development was
suspended in September 2005 based on portfolio management and
commercial factors. The increase in non-cash stock-based compensation
was due primarily to the adoption of SFAS No. 123R on January 1, 2006.
General and Administrative Expenses
General and administrative (G&A) expenses were $3.6 million in the
first quarter of 2006, including $0.8 million of non-cash stock-based
compensation, as compared with $3.0 million in the first quarter of
2005, which included $0.3 million of non-cash stock-based
compensation. The increase in G&A expenses was due primarily to higher
non-cash stock-based compensation expenses related to the adoption of
SFAS No. 123R on January 1, 2006.
Cash Guidance for 2006
Alnylam continues to expect that its cash, cash equivalents and
marketable securities balance will be greater than $115 million at
December 31, 2006.
"We continued to execute on our overall financial objectives this
quarter," said Patricia Allen, Vice President, Finance at Alnylam. "As
we projected late last year, we are now starting to see a significant
step-up in revenue as a result of our value-creating partnerships with
pharmaceutical companies. We expect this level of funding to continue
to ramp up in the coming quarters. We continue to closely manage our
operating expenses even as they increased this quarter due to our
clinical and R&D activities."
First Quarter 2006 and Recent Corporate Highlights
Product Pipeline and Scientific Leadership Highlights
-- Presented Phase I Data for ALN-RSV01. Alnylam presented the
results from two Phase I clinical studies for ALN-RSV01, its
lead program for the treatment of RSV, at the 2006 Pediatric
Academic Societies' Annual Meeting. Results showed ALN-RSV01
to be safe and well tolerated when administered in relevant
doses intranasally. In the second half of this year Alnylam
expects to initiate a Phase I study with an inhaled
formulation of ALN-RSV01, and the company is currently
evaluating the initiation of an experimental infection, or
"challenge", study for later in the year. The company believes
that these efforts will enable initiation of a Phase II trial
in naturally infected RSV patients in the first half of 2007.
-- Published Findings for Systemic Delivery of RNAi Therapeutic
in Nature. The first published demonstration in non-human
primates that a systemically delivered RNAi therapeutic can
potently silence an endogenous disease-causing gene in a
clinically relevant manner was published by Alnylam scientists
in Nature. Alnylam and its collaborators demonstrated
silencing in non-human primates of the gene for apolipoprotein
B (apoB), a protein involved in cholesterol metabolism, with
clinically significant efficacy as demonstrated by reductions
in levels of cholesterol and low-density lipoproteins (LDL).
This peer-reviewed research represents a major advance because
it shows in a species closely related to man that an RNAi
therapeutic can be effective when delivered systemically using
a dosage appropriate for application in future human clinical
studies.
-- Pipeline Update. At the recent American Pain Society annual
meeting, Alnylam scientists and collaborators discussed
strategies for using siRNAs to mediate gene silencing as a
novel and effective approach to address the underlying
mechanisms of chronic pain. Pre-clinical findings to date
demonstrate that a cholesterol-conjugated siRNA targeting
NaV1.8, a gene known to play a significant role in chronic
neuropathic pain, is efficacious in vivo against
experimentally induced chronic pain.
Business Execution Highlights
-- Signed New Alliance with Novartis for Pandemic Flu. Alnylam
and Novartis formed a new collaboration to develop RNAi
therapeutics for pandemic flu. This new alliance leverages
Alnylam's expertise in RNAi and Novartis' capabilities and
experience in bringing innovative therapeutics to patients. In
this collaboration, Novartis is providing significant funding
and Alnylam and Novartis will share potential profits. As
stated in December 2005, Alnylam expects to file an IND for
pandemic flu as early as the end of 2006.
-- Completed Successful Follow-On Offering. The company offered
5.1 million shares of its common stock at $13.00 per share
resulting in $62.2 million in net proceeds.
-- Entered into Three Relationships for Access to Delivery
Technologies. Alnylam formed three new relationships which
provide access to key technologies for the systemic delivery
of RNAi therapeutics.
-- Created Near-Term Value with New Licensing Agreements. Alnylam
continues to grant licenses to its fundamental intellectual
property estate. To date in 2006, the company has granted
licenses under the "Kreutzer-Limmer" patent family to:
Dharmacon, Inc., a business unit of the Fisher Biosciences
group and a leading supplier of innovative RNA and RNAi
research products; and Integrated DNA Technologies, Inc., a
major supplier of custom nucleic acids in the U.S.
Intellectual Property Leadership Highlights
-- Announced Allowance of U.S. Patent Broadly Covering RNAi
Therapeutics. The United States Patent and Trademark Office
(USPTO) allowed claims in two patent applications that broadly
cover methods for making siRNAs, the molecules that mediate
RNAi. The USPTO issued "Notices of Allowance" for patent
applications 10/832,248 and 10/832,432 in the Tuschl II patent
series. The patent series is exclusively licensed to Alnylam
for RNAi therapeutics on a world-wide basis through an
agreement with Garching Innovation GmbH, the licensing agent
for the Max Planck Society. The newly allowed claims broadly
cover methods of making siRNAs, with or without chemical
modifications, for any target in mammalian cells.
Organizational Highlights
-- Honored with Prestigious James D. Watson Helix Award. Alnylam
was awarded the James D. Watson Helix award for corporate
excellence in the "emerging/mid-cap" category. The Helix
award, the biotechnology industry's sole award for outstanding
corporate achievement, honors biotechnology companies that
display leadership in three distinct areas: product
development, economic growth, and corporate citizenship.
-- Strengthened Management Team. Alnylam appointed Akshay K.
Vaishnaw, M.D., Ph.D., to the position of Vice President,
Clinical Research. At Alnylam, he is responsible for leading
and managing the company's clinical organization and is a
member of the management team.
Conference Call Information
Alnylam will host a conference call at 4:30 p.m. ET on May 9, 2006
to discuss first quarter activities and recent corporate developments.
The call may be accessed by dialing 800-901-5226 (domestic) or
617-786-4513 (international) five minutes prior to the start time, and
providing the passcode 69867838.
A replay of the call will be available from 6:30 p.m. ET on May 9,
2006 until May 16, 2006. To access the replay, please dial
888-286-8010 (domestic) or 617-801-6888 (international), and provide
the passcode 18456838. A live audio webcast of the call will also be
available on the "Investors" section of the company's website,
www.alnylam.com. An archived webcast will be available on the
company's website approximately two hours after the event, and will be
archived for 14 days thereafter.
About RNA Interference (RNAi)
RNA interference, or RNAi, is a naturally occurring mechanism
within cells for selectively silencing and regulating specific genes.
Since many diseases are caused by the inappropriate activity of
specific genes, the ability to silence genes selectively through RNAi
could provide a new way to treat a wide range of human diseases. RNAi
is induced by small, double-stranded RNA molecules. RNAi is activated
by chemically synthesized small interfering RNAs, or siRNAs, which are
double-stranded RNAs that are targeted to a specific
disease-associated gene. The siRNA molecules are used by the natural
RNAi machinery in cells to cause highly targeted gene silencing.
Alnylam's initial drug development programs are focused on Direct
RNAi(TM) therapeutics which are siRNAs administered directly to
diseased parts of the body. In parallel, the company is developing
Systemic RNAi(TM) therapeutics that travel through the bloodstream to
reach diseased parts of the body.
About Alnylam
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
applying its therapeutic expertise in RNAi to address significant
medical needs, many of which cannot effectively be addressed with
small molecules or antibodies, the current major classes of drugs.
Alnylam is building a pipeline of RNAi therapeutics; its lead program
is in Phase I human clinical trials for the treatment of respiratory
syncytial virus (RSV) infection, which is the leading cause of
hospitalization in infants in the U.S. The company's leadership
position in fundamental patents, technology, and know-how relating to
RNAi has enabled it to form major alliances with leading companies
including Merck, Medtronic, and Novartis. The company, founded in
2002, maintains global headquarters in Cambridge, Massachusetts, and
has an additional operating unit in Kulmbach, Germany. Alnylam is
honored to be the "emerging/mid-cap" company recipient of the 2006
James D. Watson Helix Award, the biotechnology industry's award for
outstanding corporate achievement. For more information, please visit
www.alnylam.com.
Alnylam Forward-Looking Statements
Various statements in this release concerning our future
expectations, plans and prospects, including, without limitation,
statements related to future expectations, plans, and prospects, and
clinical development plans for ALN-RSV01, our product goals and
business goals for 2006 and projections for the amount and sufficiency
of cash, cash equivalents and marketable securities, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to: our approach to discover and develop novel
drugs, which is unproven and may never lead to marketable products;
obtaining, maintaining and protecting intellectual property utilized
by our products; our ability to enforce our patents against infringers
and to defend our patent portfolio against challenges from third
parties; our ability to obtain additional funding to support our
business activities; our dependence on third parties for development,
manufacture, marketing, sales and distribution of our products; the
successful development of products, all of which are in early stages
of development; obtaining regulatory approval for products;
competition from others using technology similar to ours and others
developing products for similar uses; our dependence on collaborators;
and our short operating history; as well as those risks more fully
discussed in the "Risk Factors" section of our most recent report on
Form 10-K on file with the Securities and Exchange Commission. In
addition, any forward-looking statements represent our views only as
of today and should not be relied upon as representing our views as of
any subsequent date. We do not assume any obligation to update any
forward-looking statements.
Alnylam Pharmaceuticals, Inc.
Unaudited Consolidated Statements of Operations
(In thousands, except per share data)
- ----------------------------------------------------------------------
Three Three
Months Months
Ended Ended
March 31, March 31,
2006 2005
- ------------------------------------------------ ---------- ----------
Net revenues $ 5,717 $ 1,643
- ------------------------------------------------ ---------- ----------
Costs and expenses
Research and development (1) 11,930 5,372
General and administrative (1) 3,584 2,952
- ------------------------------------------------ ---------- ----------
Total operating costs and expenses 15,514 8,324
- ------------------------------------------------ ---------- ----------
Loss from operations (9,797) (6,681)
- ------------------------------------------------ ---------- ----------
Other Income (Expense)
Interest income 1,260 264
Interest expense (238) (225)
Other income (expense), net (85) 42
- ------------------------------------------------ ---------- ----------
Total other income (expense) 937 81
- ------------------------------------------------ ---------- ----------
Net loss $ (8,860)$ (6,600)
- ------------------------------------------------ ---------- ----------
Net loss per common share
Net loss per common share (basic and diluted) $ (0.30)$ (0.32)
- ------------------------------------------------ ---------- ----------
Weighted average common shares used to compute
basic and diluted net loss per common share 30,028 20,435
- ------------------------------------------------ ---------- ----------
(1) Non-cash stock-based compensation expense
included in these amounts are as follows:
Research and development $ 1,530 $ 173
General and administrative 845 307
- ------------------------------------------------ ---------- ----------
Total non-cash stock-based compensation $ 2,375 $ 480
- ------------------------------------------------ ---------- ----------
Alnylam Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Balance Sheets
(In thousands)
- ----------------------------------------------------------------------
March 31, December 31,
2006 2005
- ---------------------------------------- ------------- -------------
Cash, cash equivalents and marketable
securities $ 132,275 $ 80,002
Collaboration receivables 3,116 609
Prepaid expenses and other current
assets 1,729 1,803
Property and equipment, net 11,359 10,580
Long-term restricted cash 2,313 2,313
Intangible and other assets 2,895 3,041
- ---------------------------------------- ------------- -------------
Total Assets $ 153,687 $ 98,348
- ---------------------------------------- ------------- -------------
Other current liabilities $ 9,603 $ 7,750
Deferred revenue 18,457 20,833
Notes payable, net of current portion 5,320 5,519
Deferred rent 2,391 2,467
Total stockholders' equity 117,916 61,779
- ---------------------------------------- ------------- -------------
Total Liabilities and Shareholders'
Equity $ 153,687 $ 98,348
- ---------------------------------------- ------------- -------------
This selected financial information should be read in conjunction
with the consolidated financial statements and notes thereto included
in the Company's Annual Report on Form 10-K which includes the audited
financial statements for the year ended December 31, 2005.
CONTACT: Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
or
Patricia Allen, 617-551-8362